103 related articles for article (PubMed ID: 14515265)
1. The influence of CD95L expression on tumor rejection in mice.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
[TBL] [Abstract][Full Text] [Related]
2. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo.
Igney FH; Behrens CK; Krammer PH
Int J Cancer; 2005 Jan; 113(1):78-87. PubMed ID: 15386427
[TBL] [Abstract][Full Text] [Related]
3. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
4. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
5. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
6. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
[TBL] [Abstract][Full Text] [Related]
7. Cellular localization and function of Fas ligand (CD95L) in tumors.
Kurooka M; Nuovo GJ; Caligiuri MA; Nabel GJ
Cancer Res; 2002 Mar; 62(5):1261-5. PubMed ID: 11888887
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
[TBL] [Abstract][Full Text] [Related]
9. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
[TBL] [Abstract][Full Text] [Related]
10. The role of Fas ligand as an effector molecule in corneal graft rejection.
Stuart PM; Yin X; Plambeck S; Pan F; Ferguson TA
Eur J Immunol; 2005 Sep; 35(9):2591-7. PubMed ID: 16114107
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the proinflammatory effects of Fas ligand (CD95L).
Chen JJ; Sun Y; Nabel GJ
Science; 1998 Nov; 282(5394):1714-7. PubMed ID: 9831564
[TBL] [Abstract][Full Text] [Related]
12. Tumor counterattack: fact or fiction?
Igney FH; Krammer PH
Cancer Immunol Immunother; 2005 Nov; 54(11):1127-36. PubMed ID: 15889255
[TBL] [Abstract][Full Text] [Related]
13. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
Imai T; Adachi S; Nishijo K; Ohgushi M; Okada M; Yasumi T; Watanabe K; Nishikomori R; Nakayama T; Yonehara S; Toguchida J; Nakahata T
Oncogene; 2003 Dec; 22(58):9231-42. PubMed ID: 14647441
[TBL] [Abstract][Full Text] [Related]
14. Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor.
Shimizu M; Yoshimoto T; Sato M; Morimoto J; Matsuzawa A; Takeda Y
Int J Cancer; 2005 May; 114(6):926-35. PubMed ID: 15645421
[TBL] [Abstract][Full Text] [Related]
15. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
[TBL] [Abstract][Full Text] [Related]
16. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.
Kusuhara M; Matsue H
Exp Dermatol; 2005 Apr; 14(4):273-80. PubMed ID: 15810885
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
18. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice.
Chio CC; Wang YS; Chen YL; Lin SJ; Yang BC
Br J Cancer; 2001 Oct; 85(8):1185-92. PubMed ID: 11710833
[TBL] [Abstract][Full Text] [Related]
20. Activation of CD95L fusion protein prodrugs by tumor-associated proteases.
Watermann I; Gerspach J; Lehne M; Seufert J; Schneider B; Pfizenmaier K; Wajant H
Cell Death Differ; 2007 Apr; 14(4):765-74. PubMed ID: 17053806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
